Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 19 2022 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of July 2022
Commission
file number: 001-40231
Universe
Pharmaceuticals INC
265
Jingjiu Avenue
Jinggangshan
Economic and Technological Development Zone
Ji’an,
Jiangxi, China 343100
+86-0796-8403309
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT
INDEX
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
Universe Pharmaceuticals INC. |
|
|
Date:
July 19, 2022 |
By: |
/s/
Gang Lai |
|
|
Gang Lai |
|
|
Chief Executive Officer |
2
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Jul 2023 to Jul 2024